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INTRODUCTION
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline provides a treatment algorithm for the management of chronic obstructive pulmonary disease (COPD), of which the mainstay is bronchodilators, long-acting β2 agonists (LABAs), and long acting muscarinic antagonists (LAMAs) 1 . The effects of bronchodilators are generally assessed by pulmonary function tests, in particular, by an increase of forced expiratory volume in 1 s (FEV1).
However, COPD consists of emphysema and airway remodeling in different combinations 2 , and FEV1 as an index of assessing bronchodilator effects may not fully address the structural heterogeneity of COPD 3 . A radiological approach offers a perspective on structural changes 4-10 and regional ventilation abnormalities 11 . We and others have shown that computed tomography (CT) has the potential to detect possible regional differences of bronchodilation in the airways [12] [13] [14] [15] [16] . There have been several previous studies using CT in which bronchodilation caused by salmeterol/fluticasone combination inhaler (SFC) (an inhaled corticosteroid/LABA), tiotropium (a LAMA), and indacaterol (a LABA), alone or in combination, was evaluated quantitatively [17] [18] [19] [20] . However, they focused only on the right apical segmental bronchus. The square root of the airway wall area at an internal perimeter of 10 mm (Pi10) 21, 22 has also been used and evaluated in bronchodilation 23 . Our proprietary software for three dimensional (3D)-airway analysis has the ability to assess Ai in the 3 rd to 6 th generations of airways, and its validation and reproducibility have been confirmed 12 . Our previous study showed that 3D-CT together with our proprietary software using dual screens could detect statistically significant bronchodilation at the identical points of the 3 rd to 6 th generations of airways by one week's inhalation of SFC when the average improvement in FEV1 was as small as 180 ml 12 . Of note, in our other study using tiotropium 13 , more marked bronchodilation with tiotropium was seen in the more distal parts in the 3 rd to 6 th generations of airways, which was not found in the SFC study. 8 indacaterol about 2-3 hours before they underwent the second chest CT scans and pulmonary function tests. From the following day, they started to inhale glycopyrronium (50μg) added to indacaterol and continued until the last visit (Visit 5), which was 4 to 5 weeks after the third visit.
Patients took the inhalation of indacaterol and glycopyrronium by each Breezhaler® consecutively because Breezhaler® of a combination product of indacaterol and glycopyrronium was not available during the current study period in Japan. Patients visited the hospital for the prescriptions of indacaterol and glycopyrronium at Visit 4, two weeks after Visit 5. At the last visit (Visit 5), the third chest CT scans and pulmonary function tests were performed in the same way, about 2-3 hours after the last inhalation of glycopyrronium and indacaterol.
CT and airway, emphysema analysis
A multidetector-row spiral CT scanner with a 64-detector array (Aquilion Multi, TSX-101A/6A; Toshiba Medical Systems, Tochigi, Japan) at Hokkaido University Hospital and one with a 320-detector array (Aquilion ONE(r); Toshiba Medical Systems, Tochigi, Japan) at Shiga University of Medical Science were used. The acquisition parameters were 120 kVp, 300 mA, 64 detector × 0.5 mm collimation, slice thickness 0.5 mm, 0.5 s/rotation, and helical pitch 41 and standard reconstruction kernel FC03, FC52 kernel at Hokkaido University Hospital and 120 kVp, 210mA, 64 detector × 0.5 mm collimation, slice thickness 0.5 mm, 0.5 s/rotation, and helical pitch 58 and standard reconstruction kernel FC03, FC52 kernel at Shiga University of Medical Science Hospital.
Chest CT scans were performed with the patient in the supine position at full inspiration. Pixel size was 0.625 mm at Hokkaido University Hospital and 0.683 mm at Shiga University of Medical Science Hospital. Image data were transferred to the workstation and reconstructed into 3D chest images (Virtual place Fujin Raijin 310; AZE Ltd., Tokyo, Japan). Short axis images that were perpendicular to any bronchi in the lung were obtained. Manual corrections were added when the automatically obtained outline of airway walls was out of contour, resulting in a new circle, for the measurements of airway inner luminal area (Ai).
Eight bronchi in the right lung were assessed: apical (B1), posterior (B2), and anterior (B3) of the upper lobe, lateral (B4) and medial (B5) of the middle lobe, and anterior basal (B8), lateral basal (B9), and posterior basal (B10) of the lower lobe. The 3D images of the bronchi could be rotated to find any bifurcation, and one bronchus was chosen at each bifurcation unless either of the bronchi was obstructed. Then, Ai at the midpoint between bifurcations was measured from the 3 rd (segmental bronchus) to the 6 th generations of each airway, leading to a total of 32 measurement sites per subject. The use of two screens allowed simultaneous assessment of the same point of the same bronchi from any CT data that were taken on different occasions. Average Ai values of 32 points or average Ai values per generation were taken for analysis. The degree of bronchodilation was expressed as % improvement of Ai (ΔAi, %).
Total lung volume and volume of emphysema were measured. In short, whole lung containing airways (A) were extracted from the 3D image of the thorax including major vessels, heart and esophagus. Then the bronchial skeleton (B) was extracted from the whole lung. Total lung volume was defined as (A) -(B). Low attenuation volume (%LAV) was defined as lung low % attenuation volume, based on the threshold value of -950 HU, divided by total lung volume.
Pulmonary Function Tests
Spirometry, the measurements of the diffusing capacity of the lung for carbon monoxide (DL co ), based on the single-breath method and lung volume assessed by the helium closed-circuit method 
Statistics
Data are shown as means ± standard error of the mean (SEM) except anthropometric and the data of pulmonary function tests and %LAV at baseline. Paired Student's t-tests were used to analyze differences in mean values between baseline and post-bronchodilator values of pulmonary function tests and Ai. T-test was used for the comparisons between good responders, who exhibited an increase in FEV1 of >12% and 200 ml from baseline, and poor responders, who exhibited an increase in FEV1 of <12% and 200 ml from baseline, in monotherapy or combination therapy. Relationships between quantitative variables were examined using Spearman's rank correlation test. The differences in ΔAi, % from the 3 rd to 6 th generations were ascertained using one-way analysis of variance (ANOVA). All statistical tests were 2-sided, and values of p<0.05 were considered significant. Data were analyzed using JMP 12.0 software (SAS Institute Inc., Cary, NC, USA).
RESULTS

Data of pulmonary function tests and bronchodilation assessed by CT
Twenty-eight subjects participated in the current study. One subject discontinued the inhalation of indacaterol because of a skin eruption, but in the opinion of a dermatologist, the skin eruption was not drug-related. Another subject dropped out because of dilated cardiomyopathy that was diagnosed for the first time during this study. Some of the CT acquisition parameters were different at the baseline measurement in one patient, so that patient was excluded from the analysis. The CT images of bronchi were too poor for assessment because of improper breath-holds at 4 to 5 weeks after inhalation of indacaterol in one patient, so CT data at baseline and at 4 to 5 weeks after inhalation of glycopyrronium/indacaterol were assessed.
Eventually, the data of 25 subjects at baseline and after inhalation of glycopyrronium/indacaterol and the data of 24 subjects after inhalation of indacaterol were available for the analysis. Table 1 shows the characteristics of the subjects and the results of pulmonary function tests at baseline, Visit 2. Data are shown as mean ± standard deviation.
There are the results of pulmonary function tests at baseline (Visit 2) and at 4 to 5 weeks after inhalation of indacaterol (Visit 3) or glycopyrronium/indacaterol (Visit 5) in Table 2 . Vital capacity (VC), VC, %predicted, inspiratory capacity (IC), FVC, FVC, %predicted, FEV1, FEV1, %predicted and FRC, %predicted increased significantly with indacaterol. Inhalation of glycopyrronium/indacaterol caused further increases in VC, VC, %predicted, FEV1, and FEV1, % predicted and a decrease in RV/TLC (Table 2) . FEV1, %predicted, FRC, %predicted and RV, %predicted were significantly lower in the subjects who were good responders, who exhibited an increase in FEV1 of >12% and 200 ml with indacaterol. (Table E1 ) There were no significant differences in any parameters of pulmonary function tests at visit 3 between good responders and poor responders, who exhibited an increase in FEV1 of <12% or less than 200 ml with additional glycopyrronium. (Table E2 ) Good responders with combination therapy were older than the poor responders but no significant differences were found in any parameters of pulmonary function tests at the baseline (Visit 2). (Table E3 ) The ΔAi, % with indacaterol alone was 9.33% ± 3.59%, 19.72% ± 3.96%, 22.37% ± 5.81%, and 22.56% ± 6.10% at the 3 rd to 6 th generations, respectively, and the ΔAi, % with glycopyrronium/indacaterol was 25.69% ± 4.27%, 40.56% ± 7.00%, 56.77% ± 8.23%, and 48.26% ± 8.46%, respectively. Indacaterol and glycopyrronium/indacaterol induced significant increases in ΔAi, % at the 3 rd to 6 th generations from baseline. Glycopyrronium/indacaterol added significant bronchodilation to that with indacaterol at the 3 rd to 6 th generations (Table 3) . in several subjects at the 5 th and 6 th generations (Figure 2(b) ).
ΔAi, % with indacaterol of the 3 rd and 4 th generations (3 rd generation r=0.6067, p=0.0017, 4 th generation r=0.5419, p=0.0062) correlated significantly with ΔFEV1, % , while those correlations between ΔAi, % and ΔFEV1, % were not significant either at the 5 th generation (r=0.3731, p=0.0725) or the 6 th generation (r=0.3575, p=0.0864) (Figure 3 ). There were significant correlations of ΔAi, % with ΔFEV1, % at all of the 3 rd to 6 th generations with inhalation of glycopyrronium/indacaterol (3 rd generation r=0.6585, p=0.0003; 4 th generation r=0.7700, p<0.0001; 5 th generation r=0.5368, p=0.0063; 6 th generation r=0.5923, p= 0.0018)( Figure 4 ). In terms of other pulmonary function parameters, ΔVC, %, ΔFVC, %, and ΔFEV1, % showed significant correlations with ΔAi, % with indacaterol, while ΔVC, %, ΔFVC, %, ΔFEV1, %, ΔFEV1/FVC, ΔRV, % and ΔRV/TLC showed significant correlations with ΔAi, % with glycopyrronium/indacaterol (Table 4) . To further examine the possible site-specific differences in bronchodilation patterns induced by monotherapy and combination therapy, only subjects who were good responders, who exhibited an increase in FEV1 of >12% and 200 ml from baseline, were selected. There were 5 indacaterol and 12 glycopyrronium/indacaterol responders. There were no significant site-related differences in the magnitudes of bronchodilation caused by indacaterol and by glycopyrronium/indacaterol at any of the 3 rd to 6 th generations ( Figure 5 ).
DISCUSSION
Our proprietary software for 3D-CT analysis has an advantage in that one can detect bronchodilation at the 3 rd to 6 th generations of the airways and compare the bronchodilation before and after inhalation of a bronchodilator at the same sites. Thus, we anticipated in this study that we might detect different bronchodilation patterns by generation when induced by indacaterol alone and when induced by a combination of glycopyrronium and indacaterol. This concept originated from our two previous studies; in one study using tiotropium, we demonstrated that more marked bronchodilation was seen in the more distal parts in the 3 rd to 6 th generations of the airways, but in another study using SFC, we could not find such generation-specific differences in bronchodilation. Thus, we hypothesized that long-acting antimuscarinic agents (LAMAs) and long-acting β2 agonist (LABAs) might work at different generations of the airways.
However, in the present study, there were no site-specific differences in bronchodilation between monotherapy with indacaterol and a combination of glycopyrronium/indacaterol. The reasons why there were no site-specific differences in bronchodilation might be several. First, in this study, monotherapy and combination therapy were compared, and, thus, there was no direct comparison between LABA and LAMA. Such a direct comparison between two classes of bronchodilators (LABA vs. LAMA) might provide a better chance of finding any differences in site-specific bronchodilation patterns. Second, the small number of the subjects and the smaller magnitude of improvement in FEV1 than expected might be reasons for no significant difference between monotherapy and combination therapy. However, this is very unlikely when one takes a look at the data of good responders either to monotherapy or to combination therapy. The third possible and most plausible explanation for negative findings in this study would be that what had been found in the previous two studies indicated the difference between the two drugs (tiotropium vs. SFC) but not a difference between two classes of bronchodilators. Such differences between the two drugs might be explained not only by pharmacological characteristics of the bronchodilators themselves but also by the particle size of the inhaled drugs and/or the characteristics of the delivery device of each drug. The disease severity and inspiratory flow, which may vary among the subjects, might also affect drugs' disaggregation from carrier and consecutive distributions in the lungs.
It is of note that our methods using 3D-CT could demonstrate the bronchodilation induced by indacaterol alone and also the additional bronchodilation induced by a combination of glycopyrronium and indacaterol. As mentioned above, the magnitude of the increase in FEV1 was much smaller than had been expected before the study (90 ml with monotherapy and 180 ml with combination therapy). Despite such a small increase in FEV1, it was possible to prove that anatomical bronchodilation actually occurred at full inspiration. Another remarkable finding is that ΔFEV1 is the parameter with the best correlation with the magnitude of bronchodilation evaluated by CT among the many pulmonary function parameters. This agrees perfectly with our previous studies 12, 13 . The relatively high degree of correlation between ΔFEV1 and bronchodilation assessed by CT is of particular clinical importance because it should at least partly reflect that an increase of FEV1 by spirometry is an actual indicator of bronchodilation that evidently occurs in the proximal airways.
Another point that should be emphasized in this study is the individual dots presented in Figure   2 (a), where individual bronchodilator effects with addition of glycopyrronium are clearly shown.
Almost all of the dots are placed over the identical line at any of the 3 rd to 6 th generations of the airways, indicating that additional bronchodilation is evident by 3D-CT analysis despite an increase in FEV1 as small as 90 ml with glycopyrronium. One can see remarkable bronchodilation at the 5 th and 6 th generations in some subjects with addition of glycopyrronium who did not necessarily respond to indacaterol alone. This phenomenon reminds us of our previous study where we found that some patients with COPD are preferential responders to inhaled beta-agonists, while others are preferential responders to inhaled anticholinergics. 27 Furthermore, the pattern of bronchodilation in these subjects might be considered to be similar to those subjects we encountered in another 3D-CT airway analysis study 13 . In that study, some tiotropium responders displayed marked improvement of bronchodilation at the 5 th and 6 th generations of the airways. There are, of course, several limitations in our current methods of 3D airway analysis. Although we can select the same sites for the measurement of bronchodilation before and after, we assess only one bronchial tree of the 3 rd to 6 th generations per segment, which could result in a selection bias. Our current method also precludes an investigation of heterogeneity in bronchodilation, which could be caused by different lung pathologies of bronchial walls and/or heterogeneous distribution of inhaled bronchodilators due partly to improper inhalation. We did not use body plethysmography in this study so that we could not examine the airway resistance caused by bronchodilators. It remains possible that any parameters derived from body plethysmography could have better correlations with CT-assessed bronchodilation in comparison with spirometric data or lung volumes measured by the helium closed-circuit method. Finally, with use of any imaging modalities, we cannot get to the small airways in vivo, which should be the most vital and responsible site causing airflow limitation in COPD.
In conclusion, using our proprietary 3D-CT airway analysis, significantly more bronchodilation was demonstrated with a combination of indacaterol/glycopyrronium compared with indacaterol monotherapy in the 3 rd to 6 th generations of the airways. However, there were no generation-specific differences in bronchodilation patterns between monotherapy and combination therapy. At the second visit (Visit 2), chest CT scans followed by pulmonary function tests were performed as baseline measurements. All participants started inhalation of indacaterol on the following day and used indacaterol (150μg) once a day during the next 4 to 5 weeks.
At the third visit (Visit 3), the patients inhaled indacaterol about 2-3 hours before they underwent the second chest CT scans and pulmonary function tests. From the following day, they started to inhale glycopyrronium (50μg) added to indacaterol and continued until the last visit, which was 4 to 5 weeks after Visit 3. Patients visited the hospital for the prescriptions of indacaterol and glycopyrronium at Visit 4, two weeks after Visit 5.At the last visit (Visit 5), the third chest CT scans and pulmonary function tests were performed in the same way, about 2-3 hours after the last inhalation of glycopyrronium and indacaterol. (Figure 1(a) ), and an evident increase in Ai is found in several subjects at the 5 th and 6 th generations ( Figure1(b) ). glycopyrronium/indacaterol N=12 3 rd 4 th 5 th 6 th 3 rd 4 th 5 th 6 th Figure 5 
